These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 26990724)

  • 1. The role of Toujeo®, insulin glargine U-300, in the treatment of diabetes mellitus.
    Brown MA; Davis CS; Fleming LW; Fleming JW
    J Am Assoc Nurse Pract; 2016 Sep; 28(9):503-9. PubMed ID: 26990724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [INSULIN GLARGINE 300 U/mL (TOUJEO®)].
    Scheen AJ
    Rev Med Liege; 2016 Feb; 71(2):101-7. PubMed ID: 27141654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New Insulin Glargine 300 U/mL for the Treatment of Type 1 and Type 2 Diabetes Mellitus.
    Goldman J; White JR
    Ann Pharmacother; 2015 Oct; 49(10):1153-61. PubMed ID: 26238470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insulin glargine 300 units/mL: a guide for healthcare professionals involved in the management of diabetes.
    Strong J; Kruger D; Novak L
    Curr Med Res Opin; 2017 Apr; 33(4):785-793. PubMed ID: 28132529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and pharmacodynamics of insulin glargine 300 U/mL in the treatment of diabetes and their clinical relevance.
    Owens DR
    Expert Opin Drug Metab Toxicol; 2016 Aug; 12(8):977-87. PubMed ID: 27453980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin Glargine 300 U/mL: A Review in Diabetes Mellitus.
    Blair HA; Keating GM
    Drugs; 2016 Mar; 76(3):363-74. PubMed ID: 26821280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Switching to insulin glargine 300 U/mL: Is duration of prior basal insulin therapy important?
    Bonadonna RC; Renard E; Cheng A; Fritsche A; Cali A; Melas-Melt L; Umpierrez GE
    Diabetes Res Clin Pract; 2018 Aug; 142():19-25. PubMed ID: 29649539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Replacing Insulin Glargine with Neutral Protamine Hagedorn (NPH) Insulin in a Subpopulation of Study Subjects in the Action to Control Cardiovascular Risk in Diabetes (ACCORD): Effects on Blood Glucose Levels, Hypoglycemia and Patient Satisfaction.
    Berard L; Cameron B; Woo V; Stewart J
    Can J Diabetes; 2015 Aug; 39(4):296-301. PubMed ID: 25819531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Which patients from routine care use the new insulin analogue glargine U300 compared to patients with glargine U100 : A multicenter analysis of 14,123 patients with insulin glargine from die diabetes registries DPV and DIVE].
    Bohn B; Bramlage P; Wagner C; Kaltheuner M; Welp R; Sziegoleit S; Zimmermann A; Reuter HM; Hummel M; Gloyer J; Holl RW; Danne T
    Wien Med Wochenschr; 2018 Nov; 168(15-16):415-422. PubMed ID: 28828553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved Glycemic Control with Insulin Glargine 300 U/mL (Toujeo
    Wiesli P; Schories M
    Diabetes Ther; 2018 Dec; 9(6):2325-2334. PubMed ID: 30302721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-World Effectiveness of Insulin Glargine 300 Initiation in Switzerland.
    Thomann R; Zechmann S; Alexander-David N; Jornayvaz FR
    Diabetes Metab Syndr Obes; 2020; 13():2359-2365. PubMed ID: 32753920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of initiating insulin glargine disposable pen versus vial/syringe on real-world glycemic outcomes and persistence among patients with type 2 diabetes mellitus in a large managed care plan: a claims database analysis.
    Xie L; Zhou S; Pinsky BW; Buysman EK; Baser O
    Diabetes Technol Ther; 2014 Sep; 16(9):567-75. PubMed ID: 24735083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Insulin Glargine 300 U/mL versus 100 U/mL in Diabetes Mellitus: A Comprehensive Review of the Literature.
    Vargas-Uricoechea H
    J Diabetes Res; 2018; 2018():2052101. PubMed ID: 29619381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world rates, predictors, and associated costs of hypoglycemia among patients with type 2 diabetes mellitus treated with insulin glargine: results of a pooled analysis of six retrospective observational studies.
    Xie L; Wei W; Pan C; Baser O
    J Med Econ; 2013 Sep; 16(9):1137-45. PubMed ID: 23859434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin glargine 300 units/mL: A new basal insulin product for diabetes mellitus.
    Clements JN; Bello L
    Am J Health Syst Pharm; 2016 Mar; 73(6):359-66. PubMed ID: 26953280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination therapy with insulin glargine and exenatide: real-world outcomes in patients with type 2 diabetes.
    Levin P; Wei W; Wang L; Pan C; Douglas D; Baser O
    Curr Med Res Opin; 2012 Mar; 28(3):439-46. PubMed ID: 22216894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ultra-long-acting insulins: A review of efficacy, safety, and implications for practice.
    Davis CS; Fleming JW; Malinowski SS; Brown MA; Fleming LW
    J Am Assoc Nurse Pract; 2018 Jul; 30(7):373-380. PubMed ID: 29979295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. U300 Insulin Glargine: A Novel Basal Insulin for Type 1 and Type 2 Diabetes.
    Rosselli JL; Archer SN; Lindley NK; Butler LM
    J Pharm Technol; 2015 Oct; 31(5):234-242. PubMed ID: 34860934
    [No Abstract]   [Full Text] [Related]  

  • 19. [New insulin types in type 1 diabetes mellitus].
    Mesa J
    Med Clin (Barc); 2015 Jul; 145(2):70-5. PubMed ID: 25200067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insulin glargine: a new basal insulin.
    Levien TL; Baker DE; White JR; Campbell RK
    Ann Pharmacother; 2002 Jun; 36(6):1019-27. PubMed ID: 12022906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.